Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department

2022-05-18
|
Page View:
Recently, Shanghai Medicilon Inc. (Medicilon, stock code: 688202.SH) announced the appointment of Dr. Jing Deng as the Vice President of the Pharmacology and Biology Department.

Dr. Jing Deng as Vice President of Pharmacology Pharmacodynamics and Biology Department.png

Dr. Jing Deng, Vice President of Pharmacology, Pharmacodynamics and Biology Department

Dr. Jing Deng obtained her Ph.D. degree from McGill University in the Department of Pharmacology and Therapeutics, and completed a postdoctoral program at Harvard Medical School. She is a member of leading biomedical research societies, including Society of Functional Precision Medicine (SFPM), American Society of Hematology (ASH), American Association of Cancer Research (AACR), and American Chinese Medical Association (ACMA). She is also recognized by a number of leadership awards, including Jiangsu Innovation and Entrepreneurship Award, and Suzhou Innovation and Entrepreneurship Award.
In her over twenty years’ career in biomedical science, Dr. Deng has been instrumental in applying principles of molecular pharmacology, functional genomics and proteomics in translational medicine research. Some of her achievements include : 1) as a key contributor for the translational biomarker development during the collaborative projects between Dana-Farber Cancer Institute and AbbVie for the phase 1 and 2 study of the first-in-class BCL-2 selective inhibitor (venetoclax, ABT-199); 2) providing the first evidence in the world , from the mitochondrial level, that BTK inhibitors (ibrutinib and acalabrutinib) can enhance the anti-leukemic activity of BCL-2 antagonist venetoclax, which is the rationale underlying the current Gold Standard combination therapy for CLL ; 3) development of the BH3 profiling technology for better predicting patient response in cancer therapy. In the past few years, Dr. Deng has presented more than 10 significant drug discovery projects in world conferences; and published several high impact research articles in the field.
Besides her profound academic attainments, Dr. Deng has also demonstrated excellent leadership in the process of building world-class translational team and drug discovery R&D platforms. In China, her work leads to more than fifteen IND globally, and six orphan drug designations (ODD) granted by the FDA.
Before joining Medicilon, Dr. Deng had served as the head of translational research at Ascentage Pharma for five years, and prior to that, as an investigator in translational research at world-leading biomedical institutes, including Harvard Cancer Center / Dana-Farber Cancer Institute, Skirball Institute of Biomolecular Medicine of New York University, Montreal Cancer Research Institute, for a period of more than fifteen years.
Dr. Chunlin Chen, Founder and CEO of Medicilon, said, "I am very excited about Dr. Deng joining Medicilon.  Dr. Deng has profound knowledge, has a unique understanding of innovative drug development and a global vision, and has made remarkable achievements in global academic research and international collaboration.  It is believed that the addition of Dr. Deng will help Medicilon implement its growth strategy in the global market and enhance the influence of Medicilon in preclinical research and development services for biopharmaceutical."
Dr. Deng expressed, "It's an honor to be a part of Medicilon senior management team. I am aligned with Medicilon's mission to continuously building and strengthening the innovative R&D service platforms to facilitate novel drug development globally. I look forward to bringing the Medicilon team to work closely with our partners to expedite world-class drug discovery and development processes, and through the collective efforts, bring more significant therapeutics for unmet medical needs. "
Contact us:
email:marketing@medicilon.com
Return
Relevant newsRelevant news